Novonesis (NVZMY)
OTHER OTC:NVZMY
Want to see NVZMY full AI Analyst Report?
Top Page
Novonesis
(OTC:NVZMY)
Select Model
Select Model
Rating:60Neutral
Price Target:
$63.00
▼(-0.65% Downside)
Action:Reiterated
Date:05/09/26
The score is supported by strong current operating/cash performance and a constructive earnings update with reiterated guidance and margin resilience. It is held back primarily by extremely expensive valuation (very high P/E) and only middling technical setup, with additional caution from historical volatility in annual results and leverage signals.
Positive Factors
Diversified biosolutions across food, home care, ag and industrial markets
A broad portfolio selling enzymes, strains and cultures into multiple end markets reduces reliance on any single cycle. Durable B2B relationships, technical service embedment and repeat production demand support steady recurring revenue and multiple structural growth avenues over years.
Negative Factors
Historical volatility in annual results and cash flows
Material swings in annual revenue, margins and cash flow reduce forecasting visibility and increase execution risk. Such volatility complicates multi‑year planning, raises working‑capital sensitivity and can amplify the impact of cyclical end‑market slowdowns on returns and investment plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified biosolutions across food, home care, ag and industrial markets
A broad portfolio selling enzymes, strains and cultures into multiple end markets reduces reliance on any single cycle. Durable B2B relationships, technical service embedment and repeat production demand support steady recurring revenue and multiple structural growth avenues over years.
Read all positive factors
Novonesis (NVZMY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.03B
Dividend Yield1.51%
Average Volume (3M)1.56K
Price to Earnings (P/E)221.3
Beta (1Y)0.16
Revenue Growth11.79%
EPS Growth40.66%
CountryUS
Employees10,582
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)3.24
Shares Outstanding414,555,050
10 Day Avg. Volume2,114
30 Day Avg. Volume1,559
Financial Highlights & Ratios
PEG Ratio12.64
Price to Book (P/B)15.45
Price to Sales (P/S)40.34
P/FCF Ratio223.41
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.44
Enterprise Value/Gross Profit4.67
Enterprise Value/Ebitda7.98
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.38
Revenue Forecast (FY)$5.18B
Novonesis Business Overview & Revenue Model
Company Description
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions ...
How the Company Makes Money
Novonesis makes money primarily by selling biosolutions—especially enzyme products and microbial-based ingredients—to business customers (B2B) across multiple industries. Revenue is generated from (1) product sales of formulated enzymes and enzyme...
Novonesis Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 20, 2026
Earnings Call Sentiment Positive
The call conveys a positive operational and financial start to 2026: solid 7% organic growth, improved gross margin (+120 bps), strong cash flow and EPS (+8%), successful financing and ongoing integration synergies from the Feed Enzyme Alliance. Notable near-term headwinds include currency impacts, higher operating expenses and a temporary CapEx step-up, plus segment-specific softness in North American probiotics and timing-driven declines in tech/plant. Management maintains confident full-year guidance (5%–7% organic growth; 37%–38% adj. EBITDA margin) and reiterates medium-term targets, indicating that positives (growth, margins, cash, strategic M&A and product launches) materially outweigh the transitory negatives.Positive Updates
Strong Top-Line Growth
Group organic sales grew 7% in Q1 2026 (reported EUR sales +4%), driven by volume growth; sales synergies and pricing each contributed ~1 percentage point and M&A added +3%. The outlook for 2026 organic sales growth is maintained at 5%–7% (includes ~1 ppt effect from exiting certain countries).
Negative Updates
Currency Headwinds
Currency moves created a sizeable headwind: currencies reduced reported sales by ~6 percentage points in Q1 and the full-year EBITDA margin is expected to face ~0.5 ppt of FX headwind.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Top-Line Growth
Group organic sales grew 7% in Q1 2026 (reported EUR sales +4%), driven by volume growth; sales synergies and pricing each contributed ~1 percentage point and M&A added +3%. The outlook for 2026 organic sales growth is maintained at 5%–7% (includes ~1 ppt effect from exiting certain countries).
Read all positive updates
Company Guidance
Management reiterated full‑year guidance after a strong Q1 (organic sales +7%, reported sales -4%, adjusted EBITDA margin 37.8%, adjusted EPS €0.57, operating cash flow €167.1m, Q1 CapEx €93.1m/8.3% of sales, free cash flow before acquisitions €74m): they expect organic sales growth of 5–7% (including close to a 1 percentage‑point impact from exiting certain countries), driven mainly by volume with ~1 p.p. from sales synergies, a good ~1 p.p. from pricing (deferred revenue to add ~1 p.p. in Human Health), and an adjusted EBITDA margin of 37–38% (expanding versus 2025 while absorbing ~0.5 p.p. FX headwind and higher input costs; Feed Enzyme Alliance contributing ~50 bps), CapEx to step up to 12–14% of sales in 2026 (including ~1 p.p. annual ERP impact and investments to double U.S. dairy culture capacity and develop the Thailand facility), and year‑end net debt/EBITDA around 1.7x; the outlook is based on current trade tariffs and FX and assumes a smaller Q2 inventory timing benefit in Animal that is neutral for the full year.Novonesis Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
58
Neutral
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.07B | 4.16B | 3.83B | 17.90B | 17.55B | 14.95B |
| Gross Profit | 5.79B | 2.24B | 1.81B | 9.72B | 9.58B | 8.62B |
| EBITDA | 3.39B | 1.39B | 8.07B | 5.47B | 6.12B | 5.40B |
| Net Income | 599.97M | 583.60M | 305.80M | 3.02B | 3.68B | 3.15B |
Balance Sheet | ||||||
| Total Assets | 16.54B | 16.35B | 15.20B | 28.39B | 27.98B | 24.77B |
| Cash, Cash Equivalents and Short-Term Investments | 329.74M | 295.60M | 284.00M | 1.12B | 1.12B | 1.04B |
| Total Debt | 3.22B | 22.45B | 1.80B | 7.73B | 411.00M | 482.00M |
| Total Liabilities | 5.61B | 5.49B | 4.02B | 14.04B | 13.76B | 12.56B |
| Stockholders Equity | 10.93B | 10.86B | 11.18B | 13.98B | 13.84B | 11.83B |
Cash Flow | ||||||
| Free Cash Flow | 3.17B | 750.70M | 660.10M | 2.10B | 1.12B | 2.82B |
| Operating Cash Flow | 4.28B | 1.22B | 1.02B | 4.15B | 4.01B | 4.06B |
| Investing Cash Flow | -3.45B | -1.97B | -199.70M | -2.13B | -2.67B | -2.75B |
| Financing Cash Flow | -1.03B | 753.30M | -703.20M | -1.89B | -1.25B | -1.59B |
Novonesis Technical Analysis
Positive
63.41
Price Trends
58.87
Positive
59.86
Positive
61.02
Negative
Market Momentum
-0.20
Positive
54.26
Neutral
75.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVZMY, the sentiment is Positive. The current price of 63.41 is above the 20-day moving average (MA) of 59.82, above the 50-day MA of 58.87, and above the 200-day MA of 61.02, indicating a neutral trend. The MACD of -0.20 indicates Positive momentum. The RSI at 54.26 is Neutral, neither overbought nor oversold. The STOCH value of 75.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVZMY.
Novonesis Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $19.73B | 29.17 | -0.16% | 1.74% | -22.51% | 63.47% | |
66 Neutral | $19.22B | 27.47 | 5.90% | 2.41% | -5.60% | ― | |
65 Neutral | $24.02B | 15.65 | 31.80% | 2.71% | -3.94% | 18.25% | |
64 Neutral | $12.88B | 70.63 | 21.80% | 1.96% | 5.68% | 3.81% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | $28.03B | 221.27 | 5.52% | 1.51% | 11.79% | 40.66% | |
52 Neutral | $22.50B | 51.88 | -7.44% | 12.78% | -21.87% | -176.90% |
* Basic Materials Sector Average
NVZMY
Novonesis
60.18
-9.30
-13.38%
IFF
International Flavors & Fragrances
75.28
2.06
2.81%
LYB
LyondellBasell
69.72
18.35
35.72%
PPG
PPG Industries
107.78
0.56
0.52%
RPM
RPM International
100.90
-8.88
-8.09%
DD
DuPont de Nemours
48.12
20.51
74.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.